Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

SAN DIEGO, Aug. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Light Study independent Data Monitoring Committee has recently confirmed that sufficient major adverse cardiovascular events (MACE) are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave® New Drug Application (NDA) by year end. The DMC also recommended that the Light Study continue as planned with no changes to the protocol.

"I'm proud of the progress made by our Light Study team," said Michael Narachi, Chief Executive Officer of Orexigen. "We remain focused on trial execution and launch preparation and look forward to the interim analysis and upcoming regulatory submissions."

Orexigen also today reiterated its plan to submit a Marketing Authorization Application (MAA) for Contrave® to the European Medicines Agency (EMA) in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.

About Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave.
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Calif., Oct. 19, 2011 Process automation specialist Endress+Hauser ... company that develops, produces and distributes sensors, hardware and ... to strengthen its position in the area of biotechnology ... important role in the future, not only in the ...
... Applications International Corporation (SAIC) (NYSE: SAI ) ... National Institute of Allergy and Infectious Diseases (NIAID), part ... preclinical services for the development of biopharmaceutical products for ... the end of fiscal year 2011.  The total funding ...
... NEW YORK, Oct. 19, 2011 ... research report is available in its ... Erythematosus Therapeutics (SLE) - Pipeline Assessment ... http://www.reportlinker.com/p0656881/Systemic-Lupus-Erythematosus-Therapeutics-SLE---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
Cached Biology Technology:Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3SAIC Awarded Contract by National Institute of Allergy and Infectious Diseases 2Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 2Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 3Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 4Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 5Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 6Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 7Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 8Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 9Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 10
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Virus (HCV) infects up to 500,000 people in the ... is the single biggest cause of people requiring a ... with groups across Europe and the USA, scientists from ... may be a significant step towards a vaccine. ...
... The Simons Foundation, through its Autism Research Initiative, has ... University Cell and DNA Repository (RUCDR) to establish a ... will be collected from 2,000 families that have a ... this project is known, will constitute the core resource ...
... may be to blame for the gradual extinction of ... according to Ulrich Kutschera and colleagues from the University ... in Austria. Their findings show that human-induced temperature ... of Austria may have led to the near extinction ...
Cached Biology News:Possible hepatitis C vaccine 2Rutgers Genetics receives $7.8 million for autism research 2Rutgers Genetics receives $7.8 million for autism research 3Role reversal as humans suck life out of leeches 2